ERBB2 and breast carcinoma: Overexpression of the estrogen receptor in breast cancer predicts sensitivity to anti-endocrine therapy like tamoxifen (24) whereas overexpression of the HER2 gene or gene amplification in gastric and breast cancers predicts response to anti-Her2 drugs like trastuzumab.